New drugs for the treatment of epilepsy: A practical approach

Postgraduate Medical Journal

Volumn 80, Issue 948, 2004, Pages 581-587

  Beyenburg, S ^a   Bauer, J ^b   Reuber, M ^c  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b UNIVERSITY OF BONN   (Germany)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID DERIVATIVE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARBONATE DEHYDRATASE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLUTAMIC ACID; HORMONE; LAMOTRIGINE; LIVER ENZYME; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SODIUM; TESTOSTERONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; ANOREXIA; APLASTIC ANEMIA; BEHAVIOR DISORDER; BLOOD TOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; DEPRESSION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; EYE DISEASE; FATIGUE; FETUS MALFORMATION; FOCAL EPILEPSY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; INSOMNIA; INTRAOCULAR HYPERTENSION; LIVER TOXICITY; MENTAL DISEASE; MONOTHERAPY; MYOPIA; NEPHROLITHIASIS; NONHUMAN; OUTCOMES RESEARCH; PARESTHESIA; PHARMACOKINETICS; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; TREMOR; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; COGNITION DISORDERS; EPILEPSY; HUMANS;

EID: 6344229631     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.019976     Document Type: Review

References (83)

1. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. Acta Neurol Scand 1996;94:367-77.
2. Gilliam FG. The impact of epilepsy on subjective health status. Curr Neurol Neurosci Rep 2003;3:357-62.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19.
4. Bauer J. Antiepileptische Kombinationstherapie. Rationale Konzepte versus reelle Effektivität. Fortschr Neurol Psychiatr 1998;66:414-26.
5. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 2002;50:21-32.
6. Marson AG, Kadir ZA, Mutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
7. Lindberger M, Alenius M, Frisen L, et al. Gabapentin versus vigabatrin as first add-on for patients with partial seizures that failed to respond to monotherapy: a randomised, double-blind, dose titration study. GREAT Study Investigators Group. Gabapentin in refractory epilepsy add-on treatment. Epilepsia 2000;41:1289-95.
8. Stephen LJ, Brodie M. Seizure-freedom with more than one antiepileptic drug. Seizure 2002;6:349-51.
9. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group. Epilepsy Res 1997;26:423-32.
10. Czuczwar SJ, Borowicz KK. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002;52:15-23.
11. Gupta AK, Jeavons PM. Complex partial seizures: EEG foci and response to carbamazepine and sodium valproate. J Neurol Neurosurg Psychiatry 1985;48:1010-14.
12. Bauer J, Reuber M. Medical treatment of epilepsy. Expert Opin Emerg Drugs 2003;8:457-67.
13. National Institute of Clinical Excellence. Final appraisal determination - newer drugs for epilepsy in adults. http://www.nice.org.uk/pdf/ Epilepsy_adult_FAD.pdf.
14. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-72.
15. Ben-Menachem E. Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord 2003;5(suppl 1):S51-S55.
16. Ben-Menachem E. Levetiracetom: treatment in epilepsy. Expert Opin Pharmacother 2003;4:2079-88.
17. Bourgeois BF. Chronic management of seizures in the syndromes of idiopathic generalized epilepsy. Epilepsia 2003;44(suppl 2):S27-32.
18. Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother 2003;4:243-51.
19. Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003;60(suppl 4):S2-S12.
20. Beydoun A, Kutluay E. Conversion to monotherapy: clinical trials in patients with refractory epilepsy. Neurology 2003;60:S13-25.
21. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001;90:21-34.
22. Marson AG, Chadwick DW. New drug treatments for epilepsy. J Neurol Neurosurg Psychiatry 2001;70:143-48.
23. Wilson EA, Sills GJ, Forrest G, et al. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res 1998;29:161-66.
24. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia 2003;44(suppl 4):3-10.
25. Brodie MJ, Chadwick DW, Anhut H, et al. for the Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
26. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:476-79.
27. Brodie MJ. A multicenter double-blind randomized comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia 1998;39(suppl 6):72.
28. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
29. Steiner TJ, Dellapartas CI, Findley U, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999;40:601-17.
30. Nieto-Barrera M, Brozmanova M, Capavilla G, et al. Lamictol vs Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46:145-55.
31. Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-96.
32. Gilliam FG, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25.
33. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-7.
34. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36.
35. Stephen U, Kwan P, Shapiro D, et al. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-6.
36. Barrett C, Richens A. Epilepsy and pregnancy: report of an epilepsy research foundation workshop. Epilepsy Res 2003;52:147-87.
37. Marrell MJ, Isojarvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-99.
38. Aldenkamp AP, Arends J, Bootsma HP, et al. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002;43:19-26.
39. Aldenkamp AP, Krom MD, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 2003;44(suppl 4):21-29.
40. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003;63:2029-50.
41. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-71.
42. Schmidt D, Sachdeo R. Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000;1:396-405.
43. Bong L, Goa K. Oxcarbazepine: a review of its use in children with epilepsy. Paediatr Drugs 2003:5:557-73.
44. Smith PEM. Clinical recommendations for oxcarbazepine. Seizure 2001;10:87-91.
45. Homberg V, Kowalik A, Schulze-Banhage A. Ad-hoc Umstellung von Carbamazepin zu Oxcarbazepin. Effizienz und Verträglichkeit. Eine retropsektive Analyse. Nervenarzt 2001;72:918-23.
46. Sachdeo RC, Wasserstein A, Mesenbrink PJ, et al. Effects of Oxcarbazepine on sodium concentration and water handling. Ann Neurol 2002;51:613-20.
47. Kutluay E, McCague K, D'Souza J, et al. Safety and tolerability of Oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003;4:175-80.
48. Isojärvi JI, Pakarinen AJ, Rautio A, et al. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995:47:461-4.
49. Bauer J, Blumenthal S, Reuber M, et al. Epilepsy syndrome, focus location, and treatment affect testicular function in men with epilepsy. Neurology 2004;62:243-6.
50. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41:S3-S9.
51. Sachdeo RC, Reife RA, Lim P, et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
52. Rosenfeld WE, Sachdeo RC, Fought RE, et al. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia 1997;38(suppl 1):S34-6.
53. Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165-75.
54. Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60:196-202.
55. Waugh J, Goa KL. Topiramate: as monotherapy in newly diagnosed epilepsy. CNS Drugs 2003;17:985-92.
56. Cohen J. Levetiracetam monotherapy for primary generalized epilepsy. Seizure 2003;12:150-3.
57. Appleton RE, Peters AC, Mumford JP, et al. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-33.
58. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001;15:217-30.
59. McDonagh J, Stephen U, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003;61:1690-4.
60. Jain KK. An assessment of zonisamide as an anti-epileptic drug. Expert Opin Pharmacother 2000;1:1245-60.
61. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-6.
62. Trinka E, Dilitz E, Unterberger I, et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002;249:1417-22.
63. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.
64. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56:1424-5.
65. Rigoulot MA, Boehrer A, Nehlig A. Effects of topiramate in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic wistar AS. Epilepsia 2003;44:14-19.
66. Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002;11:406-10.
67. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999;52:1330-7.
68. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(suppl 1):S7-13.
69. Abou-Khalil B, Hemdal P, Privitera MD. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure 2003;12:141-9.
70. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003;12:131-5.
71. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy. Drugs 2002;62:593-604.
72. Meodor KJ. Newer anticonvulsants: dosing strategies and cognition in treating patients with mood disorders and epilepsy. J Clin Psychiatry 2003;64(suppl 8):30-4.
73. lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 2003;44:339-47.
74. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-63.
75. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
76. Medeiros FA, Zhang XY, Bernd AS, et al. Angle-closure glaucoma associated with ciliary body detachment in patients using topiramate. Arch Ophthalmol 2003;121:282-5.
77. Bumb A, Diederich N, Beyenburg S. Adding topiramate to valproate therapy may cause reversible hepatic failure. Epileptic Disord 2003;5:157-9.
78. Cramer JA, De Rue K, Devinsky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4:124-32.
79. Bauer J, Oehring RD, Elger CE. Generalisiertes Exanthem bei Komedikation mit Levetiracetam. Z Epileptal 2001;14:23-4.
80. Nakken KO, Eriksson AS, Lassius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003;12:42-6.
81. Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001;42:1611-13.
82. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-6.
83. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003;61:1218-21.